Extracorporeal shockwave therapy shows regeneration in hip necrosis

C.-J. Wang1, F.-S. Wang2, J.-Y. Ko1, H.-Y. Huang3, C.-J. Chen4, Y.-C. Sun2 and Y.-J. Yang2

Objectives. The effect of shockwave in osteonecrosis of the femoral head (ONFH) is poorly understood. The purpose of this study was to investigate the regeneration effects of shockwave in ONFH.

Methods. This study consisted of 14 femoral heads from 14 patients undergoing total hip arthroplasty for ONFH. Seven patients with seven hips who received shockwave prior to surgery were designated as the study group, whereas, seven patients with seven hips who did not receive shockwave were assigned to the control group. Both groups showed similar demographic characteristics. The femoral heads were investigated with histopathological examination and immunohistochemical analysis with von Willebrand factor (vWF), VEGF, platelet endothelial cell adhesion molecule-1 (PECAM-1) also referred to as (CD 31) and vascular cell adhesion molecule (VCAM) for angiogenesis, and with proliferation cell nuclear antigen (PCNA), Dickkopf-1 (DKK1) and Wntless 3a (Wnt 3) for bone remodelling and regeneration.

Results. In histopathological examination, the study group showed significantly more viable bone and less necrotic bone, higher cell concentration and more cell activities including phagocytosis than the control group. In immunohistochemical analysis, the study group showed significant increases in vWF \( (P < 0.01) \), VEGF \( (P = 0.0012) \) and CD 31 \( (P = 0.0023) \), Wnt3 \( (P = 0.0008) \) and PCNA \( (P = 0.0011) \), and decreases in VCAM \( (P = 0.0013) \) and DKK1 \( (P = 0.0007) \) than the control group.

Conclusions. Shockwave treatment significantly promotes angiogenesis and bone remodelling than the control. It appears that application of shockwave results in regeneration effects in hips with ONFH.

Key words: Extracorporeal shockwave, Regeneration, Osteonecrosis, Femoral head.

Introduction

Treatment of osteonecrosis of the femoral head (ONFH) remains controversial [1]. Conservative treatments are generally unsuccessful, and surgery is indicated in symptomatic hips with the type of procedure varying according to the stage of the disease on image studies [2–4]. For early ONFH, femoral head-preserving procedures including core decompression, vascularized or non-vascularized bone graft and osteotomy are recommended [1–4]. The results of femoral head-preserving procedures varied considerably, and most studies reported less satisfactory outcomes [5–13]. For late cases, total hip arthroplasty (THA) is usually performed [14]. In young active patients, the complications of THA are common including thigh pain, polyethylene wear, osteolysis and component loosening [15]. Therefore, an effective and non-invasive method of treatment appears very attractive.

Extracorporeal shockwave therapy (ESWT) was shown to be more effective than core decompression and non-vascularized bone grafting for early ONFH [16]. We hypothesized that ESWT may result in regeneration of the femoral head with the improvement in blood supply. The purpose of this study was to investigate the regeneration effect of shockwave in hips with ONFH.

Materials and methods

The Ethical Committee of the Institutional Review Board on Human Studies of our hospital approved this study and written informed consent was acquired from all subjects according to the Declaration of Helsinki. Between July 2004 and June 2005, 30 patients with 42 hips were treated for symptomatic ONFH at our hospital. Twenty-three patients with 35 hips with stage I, II or III lesion were treated with ESWT. The source of shockwave was from an OssaTron orthotripter (Sanuwave, Alpharetta, GA, USA). The treatment was performed on the operation table under general anaesthesia. The hip joint was properly positioned by adduction and internal or external rotation of the affected leg. The femoral artery was identified with digital palpation and confirmed with ultrasound Doppler, and was protected from direct shockwave contact. The junctional zone between avascular and normal bones of the femoral head was delineated with C-arm imaging. Four points with 1.0 cm apart within the zone were chosen with a metallic pin under C-arm imaging, and the corresponding locations were marked on the skin in the groin area. The depth of treatment was determined by adjusting the height of the table until the two ring markers of the device synchronized under C-arm imaging. Surgical lubricant was applied to the skin in contact with the shockwave tube. Each of the four locations was treated with 1500 impulses of shockwave at 28 kV (equivalent to 0.62 mJ/mm² energy flux density), and a total of 6000 shocks were applied to the femoral head as a single session [16]. After treatment, patients walked with partial weight bearing on the affected leg for 4–6 weeks. Non-narcotic analgesics such as acetaminophen were prescribed for pain. The results showed improvement in 16 patients with 28 hips and un-improved or worsened in seven patients with seven hips. There was no device-related problem. There was no systemic or neurovascular complication. Local complications included ecchymosis in five and local swelling in six, and all spontaneously resolved within a few days.

THA was performed in seven patients with seven hips of the ESWT-treated group due to failure of treatment. The time interval from ESWT to THA ranged from 12 to 24 months. In addition, seven patients with seven hips with advanced stage III or IV lesion were initially treated conservatively with analgesics and protected from weight bearing to the affected leg, and THA was performed when the symptoms became unbearable. The time interval from the initial visit to THA ranged from 4 to 20 months.

Correspondence to: F.-S. Wang, Department of Medical Research, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Kaohsiung, 833 Taiwan. E-mail: w281211@adm.cgmh.org.tw

1Department of Orthopedic Surgery, 2Department of Medical Research, 3Department of Pathology and 4Department of Arthritis and Rheumatology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Taoyuan, Taiwan. Submitted 6 August 2007; revised version accepted 9 January 2008.
When the specimens were treated with ESWT for stage I, II or III lesion. Of the patients with 28 hips 7 7 1.00

- **Aetiology**: Non-steroid 3 3 1.00, Steroid induced 4 4 1.00

**Stage of lesion**: IV 2 5 0.063, III 5 2 0.063

**Size of lesion (percentage of total surface)**: Mean ± s.d. (range) 42.0 (19–56) 0.063, 39.9 (19–56) 0.063

- **Immunohistochemical stain**: CD 31, VCAM, PCNA, DKK1 and Wnt 3 are shown in Figs 3–9, respectively.

**Histopathological examination**: The microscopic features of the immunohistochemical stains for vWF, VEGF, CD 31, VCAM, PCNA, DKK1 and Wnt 3 are referred to as (CD 31) and vascular cell adhesion molecule (VCAM) and for bone remodelling and regeneration with proliferation cell nuclear antigen (PCNA), Dickkopf-1 (DKK1) and Wnt 3a (Wnt 3).

**Immunohistochemical stain**: The harvested specimens were fixed in 4% phosphate buffer solution (PBS)-buffered paraformaldehyde for 48 h and decalcified in PBS-buffered 10% ethylenediaminetetraacetic acid (EDTA). Decalcified tissues were embedded in paraffin. The specimens were cut longitudinally into 5-µm thick sections and transferred to polylysine-coated slides. Sections of the specimens were immunostained with specific reagents for vWF, VEGF, CD 31 and VCAM to identify angiogenesis and angiogenesis-related growth and proliferating indicators; and for PCNA, DKK1 and Wnt 3 to examine bone remodelling and regeneration (Santa Cruz Biotechnology Inc., CA, USA). The immunoreactivity in specimens was demonstrated using a horseradish peroxidase (HRP)-3-, 3’-diaminobenzidine (DAB) cell and tissue staining kit (R & D Systems, Inc., MN, USA). The immunoreactivities were quantified from five areas in three sections of the same specimen using a Zeiss Axioskop 2 plus microscope (Carl Zeiss, Gottingen, Germany). All the images of each specimen were captured using a Cool CCD camera (SNAP-Pro c.f. Digital kit; Media Cybernetics, MD, USA). Images were analysed using an Image-Pro® Plus image-analysis software (Media Cybernetics). The percentage of positive immunolabelled cells over the total cells in each area was counted. Two pathologists blinded to the treatment regimens performed the measurements on all sections.

**Discussion**: The aetiologies of ONFH are multi-factorial including corticosteroid, alcohol, smoking, trauma, radiation or caisson disease and genetic [17–23]. The pathophysiology of ONFH is uncertain for most cases with speculation of vascular impairment and changes in cell biology [24, 25]. The natural history of hips with ONFH, either symptomatic or silent, usually resulted in collapse of the femoral head, and surgery became inevitable [26–29]. Core decompression is the most common procedure performed in early ONFH [5, 6, 10]. The results of core decompression varied considerably ranging from 29% to 84% in the reported literatures [1, 5, 6, 16]. The rationale of core decompression is to relieve the intra-osseous pressure of the femoral head and to promote the remodelling and regeneration of the femoral head. [5, 6, 9].
Many studies reported the reparative effects of the femoral head with different methods of non-invasive treatment for hips with early ONFH [16, 30–35]. Levin et al. [30], in an experiment in rats, reported the reparative process of hyperbaric oxygen therapy with less necrotic bone as compared with the control, and hyper-oxygenation-mediated relief of ischaemia in fibroblastic, angioblastic, osteoblastic and osteoclastic activities of rat’s femoral head. Alendronate was shown to be effective in the prevention of early collapse of the femoral head affected by osteonecrosis by inhibiting the osteoclast activities and decreasing the bone turnover [31–34]. Alendronate sodium is characterized pharmacologically by the ability to inhibit bone resorption by binding to bone mineral and subsequently inhibiting the activity of osteoclasts [36]. Part of the osteoclast inhibiting action of alendronate is mediated through an action on osteoblasts [37]. Prostacyclin analogue iloprost was reported to be effective in thromboangiitis obliterans (Buerger’s disease) with critical ischaemia and the management of bone necrosis-associated and idiopathic bone-marrow oedema [38–40]. However, the value of iloprost in hips with ONFH is unknown.

ESWT was shown to be effective in early ONFH. [16, 35] The results of our previous study showed that ESWT is

### Table 2. The results of histopathological examination

<table>
<thead>
<tr>
<th></th>
<th>Shockwave (+) (n = 7)</th>
<th>Shockwave (−) (n = 7)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viable bone (%) (range)</td>
<td>45 ± 11.9 (30–60)</td>
<td>42.8 ± 11.3 (29–57)</td>
<td>0.014</td>
</tr>
<tr>
<td>Necrotic bone (%) (range)</td>
<td>17.1 ± 7.6 (10–30)</td>
<td>16.3 ± 7.2 (9.5–29)</td>
<td>0.0047</td>
</tr>
<tr>
<td>Cartilage (%) (range)</td>
<td>5.7 ± 10.2 (0–25)</td>
<td>5.4 ± 9.7 (0–24)</td>
<td>0.4206</td>
</tr>
<tr>
<td>Fibrosis (%) (range)</td>
<td>18.6 ± 7.5 (10–30)</td>
<td>17.6 ± 7.1 (10–29)</td>
<td>0.3523</td>
</tr>
<tr>
<td>Phagocytic histiocyte (%)</td>
<td>13.6 ± 10.3 (5–35)</td>
<td>12.9 ± 9.8 (5–33)</td>
<td>0.2000</td>
</tr>
</tbody>
</table>

### Table 3. The results of immunohistochemical analysis

<table>
<thead>
<tr>
<th></th>
<th>Shockwave (+) (n = 7)</th>
<th>Shockwave (−) (n = 7)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>VWF (%) (range)</td>
<td>66 ± 5 (59–70)</td>
<td>63 ± 4.7 (56–67)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>VEGF (%) (range)</td>
<td>87 ± 5.4 (79–94)</td>
<td>83 ± 5.2 (75–89)</td>
<td>0.0012</td>
</tr>
<tr>
<td>CD 31 (%) (range)</td>
<td>62 ± 20 (35–92)</td>
<td>59 ± 19 (33–87)</td>
<td>0.0023</td>
</tr>
<tr>
<td>VCAM (%) (range)</td>
<td>12 ± 5 (8–20)</td>
<td>11.6 ± 4.5 (8–19)</td>
<td>0.0013</td>
</tr>
<tr>
<td>PCNA (%) (range)</td>
<td>85 ± 4.3 (75–80)</td>
<td>80 ± 4.3 (74–86)</td>
<td>0.0011</td>
</tr>
<tr>
<td>DKK1 (%) (range)</td>
<td>26 ± 11 (12–36)</td>
<td>25 ± 10 (12–34)</td>
<td>0.0007</td>
</tr>
<tr>
<td>Wnt3 (%) (range)</td>
<td>55 ± 1.1 (53–55)</td>
<td>52 ± 1.0 (50–53)</td>
<td>0.0080</td>
</tr>
</tbody>
</table>

The data are in mean ± s.d. (range).

![Fig. 2](https://academic.oup.com/rheumatology/article-abstract/47/4/542/1790432) Microscopic findings with HE stain showed significantly more viable bone and cell concentration and cell activity in study group than the control group.

![Fig. 3](https://academic.oup.com/rheumatology/article-abstract/47/4/542/1790432) Microscopic findings with vWF stain showed significantly more new vessels (angiogenesis) in the study group than the control group.

![Fig. 4](https://academic.oup.com/rheumatology/article-abstract/47/4/542/1790432) Microscopic features with immunohistochemical stain showed significantly higher VEGF expressions in the study group than the control group.

![Fig. 5](https://academic.oup.com/rheumatology/article-abstract/47/4/542/1790432) Microscopic features with immunohistochemical stain showed significantly more CD 31 expressions in the study group than the control group.
Effective in early ONFH with 79% clinical improvement and 39% regression of the lesion on MRI [16]. Despite good clinical results, the effect of shockwave in ONFH is poorly understood. The results of the current study demonstrated that ESWT-treated femoral heads showed significant increases in angiogenesis with new vessel formation and cell proliferation, bone remodelling and regeneration than the control. It appears that application of shockwave results in regenerative effects in hips with ONFH. The increased vascularity and bone remodelling do not necessarily assure bone resorption, loss of mechanical integrity and actually predispose to subchondral fracture and failure of the disease. Therefore, shockwave is best applied in hips with early stage ONFH before the crescent sign develops.

The exact mechanism of shockwave remains unknown. The results of our study in animal experiments demonstrated that shockwave results in regenerative effects in hips with ONFH. The increased vascularity and bone remodelling do not necessarily assure bone resorption, loss of mechanical integrity and actually predispose to subchondral fracture and failure of the disease. Therefore, shockwave is best applied in hips with early stage ONFH before the crescent sign develops.

PCNA [41, 42] and promotes osteogenesis [43–48]. It is reasonable to believe that neovascularization may play a role in the improvement of blood supply to the femoral head that in turn promotes bone remodelling and regeneration in hips with ONFH.

Conclusions

ESWT-treated hips showed significant increases in angiogenesis with new vessel formation and cell proliferation, and bone remodelling and regeneration than the controls not receiving ESWT. It appears that application of shockwave treatment results in regenerative effects in hips with ONFH.

Acknowledgements

Funding: Funds were received in total or partial support for the research or clinical study presented in this article. The funding sources were from Chang Gung Research Fund (CMRPG850301), National Science Council (92-2314-B-182A-100) and National Health Research Institute (NHRI-EX96-9423EP).

Disclosure statement: The authors have declared no conflicts of interest.

References

18 Beltran J, Herman LJ, Burk JM et al.


